Advanced search
1 file | 9.81 MB Add to list

Inflammasome signaling is dispensable for ß-amyloid-induced neuropathology in preclinical models of Alzheimer's disease

Author
Organization
Project
Abstract
Background: Alzheimer’s disease (AD) is the most common neurodegenerative disorder affecting memory and cognition. The disease is accompanied by an abnormal deposition of ß-amyloid plaques in the brain that contributes to neurodegeneration and is known to induce glial inflammation. Studies in the APP/PS1 mouse model of ß-amyloid-induced neuropathology have suggested a role for inflammasome activation in ß-amyloid-induced neuroinflammation and neuropathology. Methods: Here, we evaluated the in vivo role of microglia-selective and full body inflammasome signalling in several mouse models of ß-amyloid-induced AD neuropathology. Results: Microglia-specific deletion of the inflammasome regulator A20 and inflammasome effector protease caspase-1 in the AppNL-G-F and APP/PS1 models failed to identify a prominent role for microglial inflammasome signalling in ß-amyloid-induced neuropathology. Moreover, global inflammasome inactivation through respectively full body deletion of caspases 1 and 11 in AppNL-G-F mice and Nlrp3 deletion in APP/PS1 mice also failed to modulate amyloid pathology and disease progression. In agreement, single-cell RNA sequencing did not reveal an important role for Nlrp3 signalling in driving microglial activation and the transition into disease-associated states, both during homeostasis and upon amyloid pathology. Conclusion: Collectively, these results question a generalizable role for inflammasome activation in preclinical amyloid-only models of neuroinflammation.
Keywords
Alzheimer's disease, ss-amyloid, microglia, neuroinflammation, inflammasome, NF-KAPPA-B, NLRP3 INFLAMMASOME, APOLIPOPROTEIN-E, COMMON VARIANTS, MOUSE MODELS, BETA, MICROGLIA, NEUROINFLAMMATION, ACTIVATION, PATHOLOGY

Downloads

  • fimmu-15-1323409 (3).pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 9.81 MB

Citation

Please use this url to cite or link to this publication:

MLA
Srinivasan, Sahana, et al. “Inflammasome Signaling Is Dispensable for SS-Amyloid-Induced Neuropathology in Preclinical Models of Alzheimer’s Disease.” FRONTIERS IN IMMUNOLOGY, vol. 15, 2024, doi:10.3389/fimmu.2024.1323409.
APA
Srinivasan, S., Kancheva, D., De Ren, S., Saito, T., Jans, M., Boone, F., … van Loo, G. (2024). Inflammasome signaling is dispensable for ß-amyloid-induced neuropathology in preclinical models of Alzheimer’s disease. FRONTIERS IN IMMUNOLOGY, 15. https://doi.org/10.3389/fimmu.2024.1323409
Chicago author-date
Srinivasan, Sahana, Daliya Kancheva, Sofie De Ren, Takashi Saito, Maude Jans, Fleur Boone, Charysse Vandendriessche, et al. 2024. “Inflammasome Signaling Is Dispensable for SS-Amyloid-Induced Neuropathology in Preclinical Models of Alzheimer’s Disease.” FRONTIERS IN IMMUNOLOGY 15. https://doi.org/10.3389/fimmu.2024.1323409.
Chicago author-date (all authors)
Srinivasan, Sahana, Daliya Kancheva, Sofie De Ren, Takashi Saito, Maude Jans, Fleur Boone, Charysse Vandendriessche, Ine Paesmans, Herve Maurin, Roosmarijn Vandenbroucke, Esther Hoste, Sofie Voet, Isabelle Scheyltjens, Benjamin Pavie, Saskia Lippens, Marius Schwabenland, Marco Prinz, Takaomi Saido, Astrid Bottelbergs, Kiavash Movahedi, Mohamed Lamkanfi, and Geert van Loo. 2024. “Inflammasome Signaling Is Dispensable for SS-Amyloid-Induced Neuropathology in Preclinical Models of Alzheimer’s Disease.” FRONTIERS IN IMMUNOLOGY 15. doi:10.3389/fimmu.2024.1323409.
Vancouver
1.
Srinivasan S, Kancheva D, De Ren S, Saito T, Jans M, Boone F, et al. Inflammasome signaling is dispensable for ß-amyloid-induced neuropathology in preclinical models of Alzheimer’s disease. FRONTIERS IN IMMUNOLOGY. 2024;15.
IEEE
[1]
S. Srinivasan et al., “Inflammasome signaling is dispensable for ß-amyloid-induced neuropathology in preclinical models of Alzheimer’s disease,” FRONTIERS IN IMMUNOLOGY, vol. 15, 2024.
@article{01HRQ9PRE73G83XMSQFJFJ53B7,
  abstract     = {{Background: Alzheimer’s disease (AD) is the most common neurodegenerative disorder affecting memory and cognition. The disease is accompanied by an abnormal deposition of ß-amyloid plaques in the brain that contributes to neurodegeneration and is known to induce glial inflammation. Studies in the APP/PS1 mouse model of ß-amyloid-induced neuropathology have suggested a role for inflammasome activation in ß-amyloid-induced neuroinflammation and neuropathology.

Methods: Here, we evaluated the in vivo role of microglia-selective and full body inflammasome signalling in several mouse models of ß-amyloid-induced AD neuropathology.

Results: Microglia-specific deletion of the inflammasome regulator A20 and inflammasome effector protease caspase-1 in the AppNL-G-F and APP/PS1 models failed to identify a prominent role for microglial inflammasome signalling in ß-amyloid-induced neuropathology. Moreover, global inflammasome inactivation through respectively full body deletion of caspases 1 and 11 in AppNL-G-F mice and Nlrp3 deletion in APP/PS1 mice also failed to modulate amyloid pathology and disease progression. In agreement, single-cell RNA sequencing did not reveal an important role for Nlrp3 signalling in driving microglial activation and the transition into disease-associated states, both during homeostasis and upon amyloid pathology.

Conclusion: Collectively, these results question a generalizable role for inflammasome activation in preclinical amyloid-only models of neuroinflammation.}},
  articleno    = {{1323409}},
  author       = {{Srinivasan, Sahana and Kancheva, Daliya and De Ren, Sofie and Saito, Takashi and Jans, Maude and Boone, Fleur and Vandendriessche, Charysse and  Paesmans, Ine and  Maurin, Herve and Vandenbroucke, Roosmarijn and Hoste, Esther and Voet, Sofie and  Scheyltjens, Isabelle and Pavie, Benjamin and Lippens, Saskia and  Schwabenland, Marius and  Prinz, Marco and  Saido, Takaomi and Bottelbergs, Astrid and Movahedi, Kiavash and Lamkanfi, Mohamed and van Loo, Geert}},
  issn         = {{1664-3224}},
  journal      = {{FRONTIERS IN IMMUNOLOGY}},
  keywords     = {{Alzheimer's disease,ss-amyloid,microglia,neuroinflammation,inflammasome,NF-KAPPA-B,NLRP3 INFLAMMASOME,APOLIPOPROTEIN-E,COMMON VARIANTS,MOUSE MODELS,BETA,MICROGLIA,NEUROINFLAMMATION,ACTIVATION,PATHOLOGY}},
  language     = {{eng}},
  pages        = {{20}},
  title        = {{Inflammasome signaling is dispensable for ß-amyloid-induced neuropathology in preclinical models of Alzheimer's disease}},
  url          = {{http://doi.org/10.3389/fimmu.2024.1323409}},
  volume       = {{15}},
  year         = {{2024}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: